ADENOCARD
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Oct 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADENOCARD is a small-molecule injectable product approved by Astellas in 1989 for acute management of paroxysmal supraventricular tachycardia (PSVT). The drug works through adenosine receptor agonism to slow AV nodal conduction and restore normal heart rhythm. It is administered intravenously for rapid symptomatic relief in emergency and acute care settings.
LOE Approaching
Approaching loss of exclusivity signals shrinking team investment and emphasis on cost management and generic transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ADENOCARD offers limited growth career trajectory given LOE-approaching lifecycle and zero linked job openings. Roles focus on managing decline, optimizing profitability, and transitioning to generic competition rather than driving innovation or market expansion.
Brand ManagerCommercial Operations Manager
Worked on ADENOCARD at Astellas? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.